Free Trial
NASDAQ:IMNM

Immunome Q4 2024 Earnings Report

Immunome logo
$9.87 -0.59 (-5.64%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$10.01 +0.14 (+1.37%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.68
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$2.74 million
Expected Revenue
$3.07 million
Beat/Miss
Missed by -$330.00 thousand
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 19, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Immunome's Q3 2025 earnings is scheduled for Monday, August 11, 2025

Immunome Earnings Headlines

Immunome (IMNM) Q2 Revenue Surges 382%
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat